Despite last year's sharp decline in approvals, registrations of two RNA drugs offer a window into the current state and possible future of drug development. Looking forward, the sector seeks greater clarity on the new presidential administration's priorities and the impact of new healthcare legislation. Chris Morrison reports.
This is a preview of subscription content, log in via an institution to check access.
References
Morrison, C. Nat. Biotechnol. 34, 129–132 (2016).
Anonymous. Nat. Biotechnol. 34, 1078 (2016).
Sheridan, C. Nat. Biotechnol. 34, 675–676 (2016).
Ratner, M. Nat. Biotechnol. 34, 789–790 (2016).
Shaffer, C. Nat. Biotechnol. 28, 187–188 (2010).
Morrison, C. Nat. Rev. Drug Discov. 14, 737–738 (2015).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2016. Nat Biotechnol 35, 108–112 (2017). https://doi.org/10.1038/nbt.3783
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3783
- Springer Nature America, Inc.
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Fresh from the biotech pipeline—2017
Nature Biotechnology (2018)
-
Public biotech in 2016—the numbers
Nature Biotechnology (2017)
-
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
Gene Therapy (2017)